Ampio Pharmaceuticals (DB:APH) - Prezzo delle azioni, notizie e analisi

APH Panoramica delle azioni

A biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. Maggiori dettagli

APH analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Analisi del rischio

Gli utili sono diminuiti del 28.9% all'anno negli ultimi 5 anni

Non ha una capitalizzazione di mercato significativa ( €2M )

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Le azioni sono altamente illiquide

+ 2 più rischi

Ampio Pharmaceuticals, Inc. Concorrenti

Biofrontera

XTRA:B8FK

€15.4m

SynBiotic

DUSE:SBX

€27.9m

Cantourage Group

XTRA:HIGH

€54.6m

Redx Pharma

DB:0RX

€65.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Ampio Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$3.62
Massimo di 52 settimane	US$7.40
Minimo di 52 settimane	US$2.48
Beta	2.35
1Variazione di 1 mese	0%
Variazione a 3 mesi	7.10%
Variazione di 1 anno	n/a
3Variazione a 3 anni	-81.53%
Variazione a 5 anni	-49.58%
Variazione dall'IPO	-94.09%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	APH	DE Pharmaceuticals	DE Mercato
7D	0%	-0.6%	1.0%
1Y	n/a	-18.8%	7.7%

Ritorno vs Industria: Dati insufficienti per determinare come si è comportato APH rispetto al settore German Pharmaceuticals.

Rendimento vs Mercato: Dati insufficienti per determinare la performance di APH rispetto al mercato German.

Volatilità dei prezzi

Is APH's price volatile compared to industry and market?
APH volatility
APH Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.4%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: APH non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di APH nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	5	Mike Martino	ampiopharma.com

Ampio Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Ampio Pharmaceuticals con la sua capitalizzazione di mercato?
APH statistiche fondamentali
Capitalizzazione di mercato	€1.47m
Guadagni(TTM)	-€8.17m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.2x

Rapporto P/E

APH è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
APH Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$8.80m
Guadagni	-US$8.80m

Ultimi guadagni dichiarati

Sep 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-10.57
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato APH nel lungo periodo?

Vedi performance storica e confronto

APH Panoramica delle azioni

Analisi del rischio

Ampio Pharmaceuticals, Inc. Concorrenti

XTRA:B8FK

€15.4m

DUSE:SBX

€27.9m

XTRA:HIGH

€54.6m

DB:0RX

€65.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Recent updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Levi & Korsinsky Notifies Ampio Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NYSE to Commence Delisting Procedure for Ampio Pharmaceuticals' Common Stock

Glancy Prongay & Murray LLP Files A Class Action Lawsuit Against Ampio Pharmaceuticals, Inc

Robbins LLP Files A Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc

Ampio Pharmaceuticals, Inc., Annual General Meeting, Aug 10, 2022

Ampio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Less than half of directors are independent

Ampio Pharmaceuticals, Inc. Announces Executive Changes

Ampio Provides Regulatory Update

Ampio Pharmaceuticals Releases Positive Phase 3 Data Analysis for Ampion Targeting Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals Appoints Elizabeth Varki Jobes as Member of the Board and as Member of the Nominating and Corporate Governance Committee of the Board

Less than half of directors are independent

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Ampio Pharmaceuticals, Inc. Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial

Ampio Pharmaceuticals, Inc. Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

Ampio Pharmaceuticals Reveals Early Positive Results for Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals, Inc. Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion

Ampio Pharmaceuticals, Inc. Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals Provides Update on Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of Covid-19 Patients

Ampio Pharmaceuticals, Inc. Receives Feedback from the FDA on Ampio’s Proposed Modifications to the Special Protocol Asssessment for Ampion Treatment of Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals, Inc. Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

Ampio Pharmaceuticals, Inc. Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

New 90-day high: €0.98

Ampio Pharmaceuticals, Inc. Announces the AP-014 Phase I Inhaled Ampion™ Clinical Study In COVID-19 Patients

Ampio Pharmaceuticals, Inc. Announces its Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Begins Phase 1 Clinical Trial of Inhaled Ampion for Covid-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Ampio Pharmaceuticals, Inc. Announces the Receipt of an Investigational New Drug from the U.S. Food and Drug Administration

New 90-day high - €0.69